Anja Thielitz

Summary

Affiliation: Otto-von-Guericke University
Country: Germany

Publications

  1. ncbi Identification of extra- and intracellular alanyl aminopeptidases as new targets to modulate keratinocyte growth and differentiation
    Anja Thielitz
    Department of Dermatology and Venereology, IMTM, Leipziger Str 44, 39120 Magdeburg, Germany
    Biochem Biophys Res Commun 321:795-801. 2004
  2. ncbi [Systemic acne therapy]
    Anja Thielitz
    ,
    J Dtsch Dermatol Ges 3:366-78; quiz 379-80, 382. 2005
  3. ncbi Inhibitors of dipeptidyl peptidase IV and aminopeptidase N target major pathogenetic steps in acne initiation
    Anja Thielitz
    Department of Dermatology and Venereology, Otto von Guericke University Magdeburg, Magdeburg, Germany
    J Invest Dermatol 127:1042-51. 2007
  4. ncbi Role of dipeptidyl peptidase IV (DP IV)-like enzymes in T lymphocyte activation: investigations in DP IV/CD26-knockout mice
    Dirk Reinhold
    Institute of Molecular and Clinical Immunology, Otto von Guericke University Magdeburg, Magdeburg, Germany
    Clin Chem Lab Med 47:268-74. 2009
  5. ncbi Possible role of DP IV inhibitors in acne therapy
    Anja Thielitz
    Department of Dermatology and Venereology, Otto-von-Guericke University, Leipziger Str. 44, D-39120 Magdeburg, Germany
    Adv Exp Med Biol 575:163-7. 2006
  6. ncbi The ectopeptidases dipeptidyl peptidase IV (DP IV) and aminopeptidase N (APN) and their related enzymes as possible targets in the treatment of skin diseases
    Anja Thielitz
    University Clinic of Dermatology and Venereology, Otto von Guericke University Magdeburg, Germany
    Front Biosci 13:2364-75. 2008
  7. ncbi DP IV/CD26, APN/CD13 and related enzymes as regulators of T cell immunity: implications for experimental encephalomyelitis and multiple sclerosis
    Dirk Reinhold
    Institute of Molecular and Clinical Immunology, Otto von Guericke University Magdeburg, Germany
    Front Biosci 13:2356-63. 2008
  8. ncbi PETIR-001, a dual inhibitor of dipeptidyl peptidase IV (DP IV) and aminopeptidase N (APN), ameliorates experimental autoimmune encephalomyelitis in SJL/J mice
    Dirk Reinhold
    Institute of Molecular and Clinical Immunology, Otto von Guericke University Magdeburg, D 39120 Magdeburg, Germany
    Biol Chem 392:233-7. 2011
  9. ncbi Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions
    Siegfried Ansorge
    IMTM GmbH, Magdeburg, Germany
    Clin Chem Lab Med 47:253-61. 2009
  10. ncbi Inhibitors of dipeptidyl peptidase IV-like activity mediate antifibrotic effects in normal and keloid-derived skin fibroblasts
    Anja Thielitz
    University Clinic of Dermatology and Venereology, Otto von Guericke University, Magdeburg, Germany
    J Invest Dermatol 128:855-66. 2008

Detail Information

Publications18

  1. ncbi Identification of extra- and intracellular alanyl aminopeptidases as new targets to modulate keratinocyte growth and differentiation
    Anja Thielitz
    Department of Dermatology and Venereology, IMTM, Leipziger Str 44, 39120 Magdeburg, Germany
    Biochem Biophys Res Commun 321:795-801. 2004
    ..Taken together, these data suggest that targeting alanyl aminopeptidases may be beneficial for psoriasis and other inflammatory skin disorders...
  2. ncbi [Systemic acne therapy]
    Anja Thielitz
    ,
    J Dtsch Dermatol Ges 3:366-78; quiz 379-80, 382. 2005
  3. ncbi Inhibitors of dipeptidyl peptidase IV and aminopeptidase N target major pathogenetic steps in acne initiation
    Anja Thielitz
    Department of Dermatology and Venereology, Otto von Guericke University Magdeburg, Magdeburg, Germany
    J Invest Dermatol 127:1042-51. 2007
    ....
  4. ncbi Role of dipeptidyl peptidase IV (DP IV)-like enzymes in T lymphocyte activation: investigations in DP IV/CD26-knockout mice
    Dirk Reinhold
    Institute of Molecular and Clinical Immunology, Otto von Guericke University Magdeburg, Magdeburg, Germany
    Clin Chem Lab Med 47:268-74. 2009
    ....
  5. ncbi Possible role of DP IV inhibitors in acne therapy
    Anja Thielitz
    Department of Dermatology and Venereology, Otto-von-Guericke University, Leipziger Str. 44, D-39120 Magdeburg, Germany
    Adv Exp Med Biol 575:163-7. 2006
  6. ncbi The ectopeptidases dipeptidyl peptidase IV (DP IV) and aminopeptidase N (APN) and their related enzymes as possible targets in the treatment of skin diseases
    Anja Thielitz
    University Clinic of Dermatology and Venereology, Otto von Guericke University Magdeburg, Germany
    Front Biosci 13:2364-75. 2008
    ..Targeting enzyme activity of DP IV and APN and their related molecules might be a novel approach for the treatment of acne, psoriasis or keloids...
  7. ncbi DP IV/CD26, APN/CD13 and related enzymes as regulators of T cell immunity: implications for experimental encephalomyelitis and multiple sclerosis
    Dirk Reinhold
    Institute of Molecular and Clinical Immunology, Otto von Guericke University Magdeburg, Germany
    Front Biosci 13:2356-63. 2008
    ..In the following, we summarize the evidence for the role of both ectoenzymes in T cell activation in vitro and in vivo and provide a rationale for the use of combined or dual ectopeptidase inhibitors to treat autoimmune diseases like MS...
  8. ncbi PETIR-001, a dual inhibitor of dipeptidyl peptidase IV (DP IV) and aminopeptidase N (APN), ameliorates experimental autoimmune encephalomyelitis in SJL/J mice
    Dirk Reinhold
    Institute of Molecular and Clinical Immunology, Otto von Guericke University Magdeburg, D 39120 Magdeburg, Germany
    Biol Chem 392:233-7. 2011
    ..Our results demonstrate that PETIR-001 exhibits a therapeutic effect on EAE in SJL/J mice. Thus, PETIR™ represents a novel and efficient therapeutic approach for immunotherapy of CNS inflammation...
  9. ncbi Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions
    Siegfried Ansorge
    IMTM GmbH, Magdeburg, Germany
    Clin Chem Lab Med 47:253-61. 2009
    ..The first active dual inhibitor, IP10.C8, has been developed by IMTM for the treatment of inflammatory skin diseases and has just entered the first phase II study...
  10. ncbi Inhibitors of dipeptidyl peptidase IV-like activity mediate antifibrotic effects in normal and keloid-derived skin fibroblasts
    Anja Thielitz
    University Clinic of Dermatology and Venereology, Otto von Guericke University, Magdeburg, Germany
    J Invest Dermatol 128:855-66. 2008
    ..Inhibition of DP IV-like enzymatic activity may therefore represent a promising therapeutic approach for the treatment of fibrotic skin disorders and keloids...
  11. ncbi Non-substrate peptides influencing dipeptidyl peptidase IV/CD26 activity and immune cell function
    Sabine Wrenger
    Institute of Molecular and Clinical Immunology, Otto von Guericke University Magdeburg, Germany
    Front Biosci 13:3194-201. 2008
    ..Further examinations are in progress to identify new physiologic, inhibitory DP IV ligands and to enlighten the mechanism underlying the DP IV-mediated effects...
  12. ncbi Novel aspects of cellular action of dipeptidyl peptidase IV/CD26
    Siegfried Ansorge
    IMTM GmbH, Department ImmunoPharm, Leipziger Str 44, D 39120 Magdeburg, Germany
    Biol Chem 392:153-68. 2011
    ..This finding suggests a crucial role of the immunosuppressive cytokine NPY in the function of DPIV in growth regulation...
  13. ncbi Topical retinoids in acne--an evidence-based overview
    Anja Thielitz
    University Clinic of Dermatology, Otto von Guericke University Magdeburg, Germany
    J Dtsch Dermatol Ges 6:1023-31. 2008
    ..The currently available evidence justifies the use of topical retinoids in most types of acne and during maintenance treatment...
  14. ncbi Attractin, a dipeptidyl peptidase IV/CD26-like enzyme, is expressed on human peripheral blood monocytes and potentially influences monocyte function
    Sabine Wrenger
    Institute of Immunology, Otto von Guericke University Magdeburg, Leipziger Str 44, 39120 Magdeburg, Germany
    J Leukoc Biol 80:621-9. 2006
    ..In summary, here, we demonstrate for the first time expression of attractin on monocytes and provide first data suggesting that drugs directed to DP IV-like enzyme activity could affect monocyte function via attractin inhibition...
  15. ncbi The transmembrane adaptor protein SIT inhibits TCR-mediated signaling
    Börge Arndt
    Institute of Molecular and Clinical Immunology, Otto von Guericke University Magdeburg, Magdeburg, Germany
    PLoS ONE 6:e23761. 2011
    ..In summary, the data identify SIT as an important modulator of TCR-mediated signaling that regulates T-cell activation, homeostasis and tolerance...
  16. ncbi Topical retinoids in acne vulgaris: update on efficacy and safety
    Anja Thielitz
    University Clinic of Dermatology and Venereology, Otto von Guericke University Magdeburg, Magdeburg, Germany
    Am J Clin Dermatol 9:369-81. 2008
    ..They are also suitable as long-term medications, with no risk of inducing bacterial resistance, for maintenance of remission after cessation of initial combination therapy...
  17. ncbi Update in retinoid therapy of acne
    Anja Thielitz
    Department of Dermatology and Venereology, Otto-von-Guericke University Magdeburg, Germany
    Dermatol Ther 19:272-9. 2006
    ..The use of isotretinoin has experienced a drawback now that its indication has been lowered from a first-line to a second-line medication...
  18. ncbi Frontiers in sebaceous gland biology and pathology
    Christos C Zouboulis
    Department of Dermatology, Dessau Medical Center, Dessau, Germany
    Exp Dermatol 17:542-51. 2008
    ..These multiple homeostatic functions award the sebaceous gland the role 'brain of the skin' and the most important cutaneous endocrine gland...